Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims

Detournay, B.; Debouverie, Marc; Ouarda, Pereira; Dominique, Seyer; Marc, Soudant; Courouve, L.; Khalil, Jomaa; Epstein, Jonathan; Guillemin, Françis

doi:10.1016/j.msard.2019.101396

Cited by 12 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, we limited our reporting of cost to MS-associated items; for example, days absent from work were included only in the case of an associated MS diagnosis. The French study assessed only direct costs, which consequently resulted in a reporting of lower amounts compared to our study [36].…”

Section: Study Objectives and Main Resultsmentioning

confidence: 87%

“…MS-associated medication expenses were the main driver of these costs. These costs are lower than those previously reported for Germany (€ 28,200 for Expanded Disability Status Scale [EDSS] stage 0-3; €44,000 for EDSS stage 4-6.5; € 62,700 for EDSS stage 7-9 [21]), Sweden (the average difference in cost of illness between MS patients and matched controls was SEK 225,923 [about €20,800] in 2012 [34]), and Spain (€ 24,272 [35]) and higher than those reported for France (€ 12,296 in 2014 [36]). One possible explanation for the higher costs in some of these earlier studies might be a selection bias in those studies based on data derived from patient interviews [35,37].…”

Section: Study Objectives and Main Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

Müller

Heidler²,

Fuchs³

et al. 2019

Neurol Ther

View full text Add to dashboard Cite

Section: Study Objectives and Main Resultsmentioning

confidence: 87%

Section: Study Objectives and Main Resultsmentioning

confidence: 99%

Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

Müller

Heidler²,

Fuchs³

et al. 2019

Neurol Ther

View full text Add to dashboard Cite

“…MS represents a social burden in countries where its incidence is high 11 – 13 linked to an early loss of productivity 14 , with life expectancy slightly reduced due to therapeutic progress 15 . In France, the average annual direct costs associated with MS were estimated at €12,296 in 2014, a global health cost of about €1.2 billion per year 16 .…”

Section: Introductionmentioning

confidence: 99%

Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France

Gbaguidi

Guillemin

Soudant

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system. An increase in MS incidence over time is reported in several regions of the world. We aimed to describe the evolution of the annual MS incidence in the Lorraine region, France, from 1996 to 2015 and to analyze potential components of a possible change by a temporal effect of age at MS onset, MS onset period, and birth cohort, overall and for each sex. Cases were identified from ReLSEP, a population-based registry of MS cases living in Lorraine, northeastern France, with MS onset between 1996 and 2015. Age-period-cohort modeling was used to describe trends in MS incidence. Annual age- and sex-standardized incidences were relatively stable: 6.76/100 000 population (95%CI [5.76–7.91]) in 1996 and 6.78/100 000 (95%CI [5.72–7.97]) in 2015. The incidence ratio between women and men was 2.4. For all time periods, the peak incidence occurred between ages 25 and 35 years. Age-period–adjusted cohort and age-cohort–adjusted period analyses did not reveal a period or cohort effect. The incidence of MS remained stable over the study period in Lorraine, and we could not identify any particular effect of disease onset period or birth period on this evolution.

show abstract

“…These findings align with recent research associating disease severity, relapses, and health care system characteristics with utilization and cost. [58][59][60][61] It is suspected that the cross-sectional design of this analysis, which was intended primarily for establishing system-level variation differences at baseline and not for establishing longitudinal causal relationships between DMT treatment and outcomes, likely contributes to the DMT relapse relationship finding here. Specifically, the established association between DMT treatment and relapses is likely more representative of a relationship between people on DMT being more likely to have relapsing forms of MS than DMT causing increased relapse rates, or that PwMS with higher relapse frequency may be more strongly encouraged to be on DMT or to change from an ineffective DMT to a new DMT.…”

Section: Individual Level-factorsmentioning

confidence: 99%

System-Level Variation in Multiple Sclerosis Care Outcomes: Initial Findings from the Multiple Sclerosis Continuous Quality Improvement Research Collaborative

Oliver

Walsh

Messier³

et al. 2022

Population Health Management

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a ''3C'' (complex, chronic, costly) condition that is a common and disabling neurological illness affecting approximately 1 million adults in the United States. MS has been studied at the basic science, individual, and population levels, but not at the system level to assess small-area variation effects on MS population health outcomes. System-level effects have been observed in other 3C conditions including cystic fibrosis, rheumatoid arthritis, and inflammatory bowel disease. The authors report here on system-level variation findings from the baseline period during the first year of the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) study. Stepwise binary logistic regression analyses were conducted to investigate system-level (small-area variation) effects on MS relapses (exacerbations), disease-modifying therapy (DMT) utilization, and brain MRI utilization, controlling for demographics (age and sex) and other potential confounders. Significant differences were observed in people with MS (PwMS) between centers for a number of demographic and disease characteristics, including sex, age, and MS subtype. Controlling for these factors, significant system-level effects were observed on outcomes, including DMT utilization, MRI utilization, and relapses. Significant relationships also were observed between outcomes and urgent care utilization, including emergency department visits and hospitalizations. This initial study provides evidence establishing the presence of system-level variation effects on MS outcomes in a multicenter population studywhere PwMS get their care can influence their outcomes. Results support continued systems-level research and improvement initiatives to optimize MS population health outcomes in this challenging and costly complex chronic condition.

show abstract

Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims

Cited by 12 publications

References 25 publications

Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine, France

System-Level Variation in Multiple Sclerosis Care Outcomes: Initial Findings from the Multiple Sclerosis Continuous Quality Improvement Research Collaborative

Contact Info

Product

Resources

About